康躍科技(300391.SZ):盛世豐華將成為公司控股股東 公司實控人擬變更為吳敏文、寧新江
格隆匯1月8日丨康躍科技(300391.SZ)公佈,公司獲悉,公司控股股東壽光市康躍投資有限公司(“康躍投資”)與深圳市盛世豐華企業管理有限公司(“盛世豐華”)於2020年1月6日簽署了《關於康躍科技股份有限公司股份轉讓協議》。根據上述協議約定,康躍投資將向盛世豐華轉讓其持有的康躍科技約1.05億股無限售條件普通股股份(佔公司股份總數的29.90%),此次股份轉讓的轉讓價格為8.8486元/股,轉讓價款共計人民幣約9.27億元。
上述股份轉讓完成後,盛世豐華將成為公司控股股東,公司的實際控制人擬變更為吳敏文、寧新江。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.